HC Wainwright Issues Pessimistic Outlook for COLL Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities researchers at HC Wainwright dropped their Q1 2025 earnings estimates for Collegium Pharmaceutical in a note issued to investors on Monday, March 24th. HC Wainwright analyst O. Livnat now anticipates that the specialty pharmaceutical company will earn $1.20 per share for the quarter, down from their previous estimate of $1.29. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q2 2025 earnings at $1.48 EPS.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%.

Other equities analysts have also recently issued research reports about the company. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a report on Friday, January 10th. Piper Sandler lowered their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Trading Down 1.3 %

COLL opened at $29.56 on Wednesday. Collegium Pharmaceutical has a one year low of $27.28 and a one year high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The stock has a market cap of $930.73 million, a price-to-earnings ratio of 12.74 and a beta of 0.99. The stock’s 50 day moving average price is $30.43 and its 200-day moving average price is $32.50.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its stake in shares of Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company’s stock valued at $50,876,000 after purchasing an additional 289,335 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after buying an additional 64,958 shares during the period. Renaissance Technologies LLC lifted its holdings in Collegium Pharmaceutical by 0.3% during the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company’s stock worth $47,603,000 after buying an additional 5,480 shares during the period. Geode Capital Management LLC boosted its position in Collegium Pharmaceutical by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company’s stock valued at $29,974,000 after acquiring an additional 5,464 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Collegium Pharmaceutical by 17.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock valued at $29,586,000 after acquiring an additional 116,327 shares during the period.

Insider Buying and Selling

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 1,949 shares of the company’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total value of $58,470.00. Following the completion of the sale, the chief financial officer now directly owns 177,195 shares in the company, valued at approximately $5,315,850. This represents a 1.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. The trade was a 18.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 109,193 shares of company stock valued at $3,243,594 over the last quarter. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.